Glycotex withdraws IPO
Glycotex, the U.S. subsidiary of Novogen, has withdrawn its initial public offering. Company officials say that they want Glycotex to push its wound healing and tissue repair drugs further along before proceeding with an IPO.
- read this release for more
ALSO: Altus Pharmaceuticals has priced its IPO of 6 million shares at $14 to $16 a share. Report
Comments